Back to Search Start Over

Evaluating tocilizumab safety and immunomodulatory effects under ocular HTLV-1 infection in vitro.

Authors :
Zhang J
Kamoi K
Zong Y
Yang M
Zou Y
Ohno-Matsui K
Source :
International immunopharmacology [Int Immunopharmacol] 2024 Aug 20; Vol. 137, pp. 112460. Date of Electronic Publication: 2024 Jun 21.
Publication Year :
2024

Abstract

There is growing interest in evaluating the safety and therapeutic potential of existing treatments such as tocilizumab (TCZ), an IL-6 receptor antagonist used to treat inflammatory diseases. However, there have been reports of increased inflammation in patients with HTLV-1 uveitis after TCZ treatment, and its ocular safety in the HTLV-1 infected state remains unknown. This study focused on assessing the impact of TCZ on HTLV-1-infected ocular cells using an in vitro model in which retinal pigment epithelial cells were cocultured with irradiated HTLV-1-infected T-cell lines. TCZ did not significantly affect cellular viability, inflammatory markers, or HTLV-1 proviral loads at various concentrations (25/50/100 µg/ml), indicating no increased risk of HTLV-1 viral infection and no exacerbation of the inflammatory aspects of HTLV-1 infection in the ocular cells. These promising results support the potential of TCZ as a safe treatment option for HTLV-1-infected patients, particularly those with eye infections.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1878-1705
Volume :
137
Database :
MEDLINE
Journal :
International immunopharmacology
Publication Type :
Academic Journal
Accession number :
38908082
Full Text :
https://doi.org/10.1016/j.intimp.2024.112460